Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 exploratory study of two-dose ATIR101 after haploidentical HSCT
2015-002821-20Phase 2Completed
- Sponsor
- Kiadis Pharma
- Start
- Jul 2015
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATIR101 in hematopoietic malignancies, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 1 more, sponsored by Kiadis Pharma. Primary endpoint: Incidence of acute graft versus host disease grade III/IV up to 180 days post-HSCT. Started Jul 2015; status: completed.
02
Drugs
ATIR101
03
Conditions
hematopoietic malignanciesacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2015-002821-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002821-20.